Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axcella Health Inc.AXLA · Entity 116059 | Chief Medical Officer | March 01, 2023 | March 03, 2023 |
| Innoviva, Inc.INVA · Entity 4679 | Chief Medical Officer | July 31, 2023 | August 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axcella Health Inc.
Report date March 01, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,883 |
Reported balance
After 2023-03-01 transaction · row 1
1 source rowRow 1 · 2023-03-01 · Sale · Disposed 679 · Balance 24,883 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.
Innoviva, Inc.
Report date July 31, 2023 · Filed August 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonqualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.55 · Expires 2033-07-31 | Direct | 60,000 |
Reported balance
After 2023-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-31 · Grant · Acquired 60,000 · Balance 60,000 F1: 25% of the options will vest on July 31, 2024 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, subject to Dr. Koziel's continuous service through the applicable vesting date, with accelerated vesting (i) in the event of a "change in control" (as defined in the Issuer's 2012 Equity Incentive Plan) in which the options are not assumed or replaced, or (ii) in the event that Dr. Koziel experiences a termination of employment by the Innoviva, Inc. without "cause" or by Dr. Kozial for "good reason" (each as defined in Dr. Koziel's employment agreement) within 12 months following a "change in control.," subject to an effective release of claims. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the options will vest on July 31, 2024 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, subject to Dr. Koziel's continuous service through the applicable vesting date, with accelerated vesting (i) in the event of a "change in control" (as defined in the Issuer's 2012 Equity Incentive Plan) in which the options are not assumed or replaced, or (ii) in the event that Dr. Koziel experiences a termination of employment by the Innoviva, Inc. without "cause" or by Dr. Kozial for "good reason" (each as defined in Dr. Koziel's employment agreement) within 12 months following a "change in control.," subject to an effective release of claims.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2023 Filed Aug 3, 2023 01:32 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNonqualified Stock Option · Derivative | 60,000 | $0.00 Strike: $13.55 | $0.00 |
DisclosureSEC source: 0001104659-23-086955 · tm2322589-3_4seq1.xml · derivative · entry 1 Koziel Margaret · CIK 0001898760 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-07-31 F1 · derivative.exercise_date: 25% of the options will vest on July 31, 2024 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, subject to Dr. Koziel's continuous service through the applicable vesting date, with accelerated vesting (i) in the event of a "change in control" (as defined in the Issuer's 2012 Equity Incentive Plan) in which the options are not assumed or replaced, or (ii) in the event that Dr. Koziel experiences a termination of employment by the Innoviva, Inc. without "cause" or by Dr. Kozial for "good reason" (each as defined in Dr. Koziel's employment agreement) within 12 months following a "change in control.," subject to an effective release of claims. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:17 UTC | Axcella Health Inc. AXLA · Entity 116059 | SaleCommon Stock | 679 | $0.58 | $393.82 |
DisclosureSEC source: 0001104659-23-028434 · tm238444-1_4seq1.xml · nonDerivative · entry 1 Koziel Margaret · CIK 0001898760 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,883 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. Read SEC document |
| February 17, 2023 Filed Feb 24, 2023 16:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001104659-23-025323 · tm236575-4_4seq1.xml · derivative · entry 1 Koziel Margaret · CIK 0001898760 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2033-02-16 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 7, 2024, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 17:52 UTC | Axcella Health Inc. AXLA · Entity 116059 | SaleCommon Stock | 547 | $2.52 | $1,378.17 |
DisclosureSEC source: 0001104659-22-098591 · tm2225410-1_4seq1.xml · nonDerivative · entry 1 Koziel Margaret · CIK 0001898760 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,562 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.50 to $2.52. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 17:04 UTC | Axcella Health Inc. AXLA · Entity 116059 | SaleCommon Stock | 590 | $2.01 | $1,186.31 |
DisclosureSEC source: 0001104659-22-067700 · tm2217610-1_4seq1.xml · nonDerivative · entry 1 Koziel Margaret · CIK 0001898760 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,109 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"), and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 16:19 UTC | Axcella Health Inc. AXLA · Entity 116059 | SaleCommon Stock | 553 | $1.86 | $1,029.58 |
DisclosureSEC source: 0001104659-22-030022 · tm228352-1_4seq1.xml · nonDerivative · entry 1 Koziel Margaret · CIK 0001898760 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,699 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"), and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.86 to $1.87. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: The Form 3 filed by the reporting person on December 13, 2021 inadvertently overstated the number of securities beneficially owned by 2,748 shares in Table I, Column 2. F4 · balance_after: Includes RSUs. Each RSU represents a contingent right to receive one share of AXLA common stock. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 17:57 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantStock Option (Right to Buy) · Derivative | 33,397 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001104659-22-019546 · tm226270d1_4seq1.xml · derivative · entry 1 Koziel Margaret · CIK 0001898760 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,397 Underlying: Common Stock · 33,397 shares Expires 2032-02-07 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 8, 2023, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 17:56 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001104659-21-149193 · tm2135309-2_4seq1.xml · derivative · entry 1 Koziel Margaret · CIK 0001898760 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-12-10 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on December 10, 2022, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.